



Using Mendelian Randomization to Decipher Mechanisms of Bone Disease

Katerina Trajanoska¹ · Fernando Rivadeneira¹

Published online: 10 September 2018
© The Author(s) 2018

Abstract

Purpose of Review This review summarizes the basic principles of Mendelian randomization (MR) and provides evidence for the causal effect of multiple modifiable factors on bone outcomes.

Recent Findings Several studies using MR approach have provided support for the causal effect of obesity on bone mineral density (BMD). Strikingly, studies have failed to prove a causal association between elevated 25(OH) D concentrations and higher BMD in community-dwelling individuals.

Summary The MR approach has been successfully used to evaluate multiple factors related to bone mineral density variation and/or fracture risk. The MR approach avoids some of the classical observational study limitations and provides more robust causal evidence, ensuring bigger success of the clinical trials. The selection of interventions based on genetic evidence could have a substantial impact on clinical practice.

Keywords Osteoporosis · Bone mineral density · Fractures · Mendelian randomization · Review

Introduction

A fundamental goal of epidemiological (observational) studies is to determine causal factors of diseases. However, in observational studies, we test for association, which by itself does not imply causation. Two logical fallacies *cum hoc ergo propter hoc* (“with this, therefore because of this”) and *post hoc ergo propter hoc* (“after this, therefore because of this”) challenge the interpretation of observational studies. The relationship between exposure (expected cause) and disease (expected outcome) can be distorted by (a) the presence of unmeasured or unaccounted confounders, (b) reverse causation, and (c) a variety of other potential biases. Although proper study designs and analytical approaches can minimize the effect of the aforementioned factors, we still fail to account for most of them. Therefore, interventions based exclusively on evidence derived from association studies might turn out fruitless.

Some factors and biomarkers identified in observational studies have failed to be confirmed by large, robust randomized control trials (RCTs). For instance, in the past several years, observational studies [1–3] and one small RCT [4] have provided encouraging evidence for the beneficial effect of the vitamin D and calcium supplements on bone health. Thus, vitamin D and calcium supplementation have been included in the clinical guidelines for osteoporosis management and fracture prevention [5, 6]. However, in the past years, from a total of 38 RCTs (14 large and 24 small), the majority failed to detect a benefit of vitamin D and calcium supplements [7–9]. Moreover, a small proportion of the trials have found modest protective effects [10], and some have even shown an increased harm (e.g., falls, fractures) [11]. Even though experimental [randomized] studies are considered to be the gold standard for estimating causality in research [12], they have their own caveats like limitations due to ethical and technical issues and the exposure cannot be randomized, or being time-consuming and frequently costly [13]. Moreover, the lack of external validity (generalizability of the treatment/condition outcomes) affects the reliability of the results from the RCTs, which may result in flawed policy recommendations. In order to overcome the limitations from the observational and experimental studies, up till now, many methods (conditioning, mechanism-based, natural experiments) for

This article is part of the Topical Collection on *Genetics*

✉ Fernando Rivadeneira
f.rivadeneira@erasmusmc.nl

¹ Departments of Internal Medicine and Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

causal inference have been developed that can be easily applied in epidemiological settings and can improve the identification of clinically relevant risk factors. Mendelian randomization is one of them. The aim of this review is to explain the basic principles of Mendelian randomization and provide examples of how Mendelian randomization has been applied to bone research.

Casual Inference: Mendelian Randomization Analysis and Principles

Mendelian randomization plays an important role in causal inference. During conception, parental gametes combine to form a zygote. Each gamete contains a different set of DNA as a result of recombination and independent assortment during conception resulting in genetically defined subgroups of individuals. The Mendelian randomization (MR) design is considered to be analogous to a RCT [14] where instead of random allocation of participants to interventions (treatments or preventive measures) individuals are randomized by nature according to carriership of gene variants that regulate susceptibility to a specific exposure (Fig. 1). Within both approaches, individuals are divided into random groups balanced across confounding factor(s). Following this principle, genetic variants associated with specific risk factors can be used as a non-confounded proxy to investigate the causal association between the risk factor in question and disease outcomes. Moreover, genetic variants have the advantages of being largely fixed since conception and remain stable throughout life. The expansion of genome wide association studies (GWAS) and improvement in array and imputations panels has enabled well-powered settings facilitating the identification of numerous genetic variants associated with different diseases and complex traits. Such large yield in genetic discoveries propelled by large-scale GWAS has improved considerably the extent of explained trait variance and the prospect of risk prediction of common diseases [15]. This also means that the MR approach leveraged by the abundance of genetic discoveries can now be easily implemented across numerous observational settings. This way, the MR approach can provide prior knowledge before launching RCTs or it can give way to more valid estimates of causal relationships in situations where an RCT cannot be conducted (e.g., smoking and alcohol intake). If MR findings provide evidence of causality for a specific marker, the next step will be to identify the correct biological pathway before performing RCTs. In addition, the MR is a simple and cost-effective method to assess causal relationships between risk factors and health outcomes. In order to obtain unbiased estimates, three key assumptions of MR need to be fulfilled with regard to the instrument: (1) genetic variants are associated with the risk factors or biomarkers under study; (2) genetic variants should not be

associated with known confounding factors; and (3) it affects the outcome only through the risk factor and not via other biological pathways (pleiotropy) (Fig. 2). The first assumption can be easily verified by exploring the data. Even if this assumption holds, we need to test the strength of the association between the genetic variants and exposure (e.g., using partial F statistic) to avoid weak instrument bias [16]. The second and third assumption can be difficult to address. First, we cannot estimate the association between the genetic variant and unobserved confounders (second assumption). However, we can still test the association with observed potential confounding factors or/and search the literature for any reported associations. Second, the presence of pleiotropy (third assumption) can be indirectly detected and corrected by using robust statistical methods [17] (e.g., MR-Egger regression, median weighted). In short, Egger regression assumes that the pleiotropic effect of the variant is independent of the phenotypic effect. If the pleiotropic effects act via a confounder of the “exposure-outcome” association, this assumption will be violated. Moreover, this will affect its associations with both the exposure and the outcome indicating the potential presence of directional pleiotropy. Finally, if the above assumptions hold, the MR can give reliable evidence for causation overcoming the typical pitfalls present in observational studies.

Mendelian Randomization Debunks the Findings from Observational Studies: an Example

It is well established that heavy alcohol drinking during pregnancy has a serious effect on diverse health outcomes of the children [18]. Currently, there is no known safe level of alcohol that can be consumed at any time during pregnancy. However, many women do drink alcohol during pregnancy, generally at a moderate level, as a result of the conflicting messages from the health guidelines. Some of them promote complete abstinence while others recommend moderate drinking. These contradicting messages largely reflect the inconsistent findings from observational studies. For example, some observational studies have found that moderate drinking during pregnancy is even associated with a better cognitive function in children [19]. Nonetheless, the association can be confounded by many socio-economic factors. Taking all these confounders into consideration does attenuate the association, but does not eliminate the effect fully possibly due to residual confounding [20].

Alcohol is metabolized in the body by several alcohol dehydrogenase (ADH) enzymes. Variation in the genes that encode these enzymes influences the metabolic rate of alcohol [21]. Slow metabolizers will be exposed to higher alcohol levels for a longer time compared to fast metabolizers. Thus, it is hypothesized that alleles which increase the metabolism of





Fig. 1 Comparison of the design of Mendelian randomization study and a randomized controlled trial



Assumptions of Mendelian Randomization Study:

- Genetic variants are associated with the risk factor
- Genetic variants are not associated with confounders
- Genetic variants influence bone outcomes only through the risk factor

Fig. 2 Directed acyclic graph (DAG) represents the relationship in a typical Mendelian randomization model

ethanol will protect against abnormal brain development in infants [20] (as a result of less pronounced exposure to alcohol). For example, researchers of the Avon Longitudinal Study of Parents and Children (ALSPAC, UK-based children cohort) found that four genetic variants in alcohol metabolizing genes were related to low IQ at age 8 in children (carriers of the “slow” metabolizing alleles) whose mothers were drinking during pregnancy [22]. Moreover, in the same study, Zuccolo et al. [20] found the same association observed by previous studies when using the observational approach, i.e., moderate drinking is associated with increased IQ. However, using the MR method, they found that children of mothers genetically predisposed to drink less were better at school than children of mothers genetically predisposed to drink more [20]. This example illustrates the benefits of the MR approach; considering that most of the observational studies found associations in the same direction, the MR studies disproved them. MR becomes quite relevant in those scenarios where the association under study is confounded by multiple factors (alcohol and cognition in this case). Other examples include studies examining the causal role of CRP [23], lipoprotein (a) [24], and vitamin D levels [25] with different cardiovascular outcomes, or the association of homocysteine levels with diabetes mellitus [26].

Mendelian Randomization in Bone Biology

The human skeleton is made of a dynamically growing tissue, essential for locomotion, structural support of soft tissues, and protection of organs. In addition, the skeleton exerts metabolic functions providing a mineral reservoir (primarily for calcium, but also for magnesium and phosphorus) and serves as a depository for cytokines and growth factors that upon release can exert local and systemic effects. Bones are constantly reshaped and renewed throughout the lifespan, through the processes of modeling and remodeling, which are under genetic and environmental control. Modeling occurs in growing bones from birth to the mid-20s, when peak bone mass is achieved. With aging, the imbalance in bone remodeling leads to loss of bone mass and deterioration of bone structure, which predispose to osteoporosis and fracture. An individual’s peak bone mass ultimately relates to lifetime risk of fracture (i.e., the higher the peak bone mass, the lower the risk). Yet, partitioning the genetic and environmental influences (risk factors) exerting an effect on bone throughout the lifetime is not trivial. The Mendelian randomization (MR) approach provides means to assess the influence of risk factors on osteoporosis outcomes, including fracture.

To date, the MR approach in the bone field has been applied predominantly to assess cause-effect relationships between different risk factors or biomarkers in relation to bone mineral density as outcome (Table 1). Among these body composition factors, inflammation markers and vitamin D levels are the

most frequently investigated exposures. In particular, MR analyses have clearly reinforced the role of low BMI as an important risk factor for loss of bone mass [27•, 28, 29]. Similarly, late puberty [30] and type 2 diabetes and associated glycemic traits [31•] have been shown to exert modest causal effects on bone outcomes; in contrast, genetically increased inflammation markers [32, 33], phosphate [34] (very low powered), and higher urate levels [35, 36] had no causal effect on skeletal outcomes including fracture risk. A recent study has found a modest effect of heel BMD on type 2 diabetes and coronary heart disease, opening the door of evaluating deeper the endocrine function of the bone [37]. Notably, studies investigating the causal role of vitamin D and milk calcium intake showed no evidence of association [38, 39, 40•, 41].

Vitamin D and Bone Mineral Density

Vitamin D is required for normal bone maturation, formation, and mineralization. Low levels of vitamin D result in hypocalcemia, hypophosphatemia, and hyperparathyroidism, which in turn can lead to impaired mineralization, bone loss, and low BMD levels. Severe lack of vitamin D is known to cause rickets (in children) and osteomalacia (in adults) [42]. Nevertheless, the influence of vitamin D on the etiology of low bone mass and the predisposition to develop osteoporosis is still unclear due to inconsistent results across clinical studies. These differences can be attributable to aspects of study design (e.g., study power, type of recruited population, or aspects affecting the vitamin D measurement, like season, thresholds, assays among others).

There are four SNPs found by GWAS to be strongly associated with 25(OH) D levels, mapping back to genes implicated in vitamin D synthesis, transport, or metabolism. These include rs2282679 in *GC* (association with 25(OH)D: $p = 1.9 \times 10^{-109}$), rs12785878 near *DHCR7* ($p = 2.1 \times 10^{-27}$), rs10741657 near *CYP2R1* ($p = 3.3 \times 10^{-20}$), and rs6013897 in *CYP24A1* ($p = 6.0 \times 10^{-10}$) [43]. The vitamin D-binding protein (DBP), a group-specific component of serum alpha globulin, is encoded by the *GC* gene and it serves as the principal protein carrier for vitamin D and its metabolites [44]. On the other hand, the *DHCR7* gene produces cholesterol, a substrate for vitamin D production. Finally, *CYP2R1* (encoding 25(OH) D synthesis) and *CYP24A1* (encoding $1\alpha 25(\text{OH})_2\text{D}$ inactivation) provide the active form of vitamin D.

Three studies have scrutinized if the relationship between vitamin D and BMD is causal. Leong et al. [38] have investigated the causal relationship between vitamin D-binding protein (DBP) levels and BMD using individual level data ($N = 2254$) from the Canadian Multicentre Osteoporosis Study (CaMos). In line with their observational results, they showed that DBP might not be a critical player in causal pathways potentially linking vitamin D to BMD. The authors also overcame the sample size limitations of the individual level setting

Table 1 Systematic literature review of applications of Mendelian randomization using bone-related phenotypes

Exposure	Cohort(s)	Number	Genetic variant(s)	MR method	Unit	Causal effect estimate	p	Ref
Obesity	Avon Longitudinal Study of Parents and Children (ALSPAC)	7470 children	FTO marker: rs9939609 MC4R marker: rs17782313 77 SNPs associated with higher BMI	Instrumental variable regression model, 2SLS	1 g change in BMC per 1 kg change in fat mass	TB-BMC, 0.02 (−0.20, 0.15)	p = 0.0002	[27••]
						UL-BMC, 0.46 (0.31, 0.61)	p = 0.03	
						LL-BMC, 0.55 (0.41, 0.68)	p = 0.002	
						LS-BMC, 0.48 (0.33, 0.63)	p = 2.3 × 10 ^{−6}	
[28]	Avon Longitudinal Study of Parents and Children (ALSPAC)	5221 children	77 SNPs associated with higher BMI	Instrumental variable regression model, 2SLS	SD change in BMD per SD increase in BMI	SK-BMD, 0.02 (−0.20, 0.15)	p = 0.78	
						UL-BMD, 0.46 (0.31, 0.61)	p < 0.001	
						LL-BMD, 0.55 (0.41, 0.68)	p < 0.001	
						LS-BMD, 0.48 (0.33, 0.63)	p < 0.001	
[29]	Cross-sectional cohort of employees of the Electricity Generating Authority in Thailand	2154 adults	FTO marker: rs9939609	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 kg/m ² change in BMI	PE-BMD, 0.39 (0.34, 0.64)	p < 0.001	
						TH-BMD, 0.02 (0.00, 0.03)	p = 0.010	
						FN-BMD, 0.01 (0.00, 0.03)	p = 0.014	
						LS-BMD, 0.00 (−0.01, 0.01)	p = NS	
Inflammation	The Rotterdam Study	6386 adults	29 SNPs associated with CRP levels 20 SNPs associated with CRP levels	Weighted genetic risk score Published GWAS summary data, IVW and WM approach	OR for fracture per 1 SD increase in CRP 1 g/cm ² change in BMD per 1 log mg/L change in total hsCRP	Fracture, 1.00 (0.99, 1.00)	p = 0.23	[32]
						FA-BMD, −0.02 (N/A)	p = 0.69	
						FN-BMD, −0.04 (N/A)	p = 0.22	
						LS-BMD, −0.04 (N/A)	p = 0.30	
Type 2 diabetes	Summary data from two consortia (DIAGRAM consortium and GEFOS consortium)	T2D, 149,821 (34,840 cases, 114,981 controls)	37 SNPs associated with increased T2D risk	Published GWAS summary data, IVW approach	SD change in BMD per odds in T2D	FN-BMD, 0.03 (0.01–0.06)	p = 0.017	[31•]
						LS-BMD, 0.02 (−0.01, −0.05)	p = 0.133	
						FN-BMD, 0.13 (0.02, 0.25)	p = 0.060	
						LS-BMD, 0.08 (−0.04, 0.21)	p = 0.064	
Fasting glucose	Summary data from two consortia (MAGIC consortium and GEFOS consortium)	BMD, 32,961 FG, 133,010 BMD, 32,961	33 SNPs associated with higher glucose levels	Published GWAS summary data, IVW approach	SD change in BMD per 1 mmol/L increase in GF	FN-BMD, 0.10 (0.02, 0.19)	p = 0.043	[31•]
						LS-BMD, 0.10 (0.01, 0.19)	p = 0.046	
						TH-BMD, −0.04 (−0.13, 0.04)	p = 0.326	
						FN-BMD, −0.04 (−0.13, 0.03)	p = 0.261	
2-h glucose	Summary data from two consortia (MAGIC consortium and GEFOS consortium)	2hGlu, 133,010 BMD, 32,961	6 SNPs associated with glucose level	Published GWAS summary data, IVW approach	SD change in BMD per 1 mmol/L increase in 2hGlu	LS-BMD, 0.05 (−0.16, 0.06)	p = 0.384	[39]
						FN-BMD, 0.05 (−0.16, 0.06)	p = 0.384	
						TH-BMD, −0.04 (−0.13, 0.04)	p = 0.326	
						FN-BMD, −0.04 (−0.13, 0.03)	p = 0.261	
Vitamin D	Cross-sectional study of unrelated Chinese Han women	1824 women	10 SNPs associated with vitamin D levels	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 SD change in DBP	TH-BMD, −0.04 (−0.13, 0.04)	p = 0.326	[39]
						FN-BMD, −0.04 (−0.13, 0.03)	p = 0.261	
						LS-BMD, 0.05 (−0.16, 0.06)	p = 0.384	
						FN-BMD, −0.04 (−0.13, 0.03)	p = 0.261	
Urate	Canadian Multicentre Osteoporosis study (CaMos)	2254 adults	rs2282679	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 SD change in DBP	FN-BMD, 0.02 (−0.03, 0.07)	p = 0.37	[40•]
						LS-BMD, 0.02 (−0.04, 0.08)	p = 0.49	
						eBMD, −0.03 (−0.05, −0.01)	p = 0.02	
						TF-BMD, −0.29 (−0.60, 0.01)	p = 0.06	
[35]	Summary data from three consortia (SUNLIGHT consortium, DIAGRAM consortium and GEFOS consortium)	Vitamin D, 42,274 BMD, 32,961 eBMD, 142,487	5 SNPs associated with vitamin D levels	Published GWAS summary data, IVW approach	1 SD change in BMD per 1 SD change in 25OHD (g/cm ² eBMD)	FN-BMD, −0.27 (−0.58, 0.03)	p = 0.08	
						LS-BMD, 0.08 (−0.32, 0.48)	p = 0.68	
						TH-BMD, 0.19 (−0.36, 0.74)	p = 0.50	
						FN-BMD, −0.19 (−0.42, 0.81)	p = 0.53	
[36]	Framingham Heart Study (FHS)	2501 adults	5 SNPs associated with urate levels	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 mmol/L change in urate levels	LS-BMD, 0.39 (−0.26, 0.98)	p = 0.26	
						TF-BMD, −0.29 (−0.60, 0.01)	p = 0.06	
						FN-BMD, −0.27 (−0.58, 0.03)	p = 0.08	
						LS-BMD, 0.08 (−0.32, 0.48)	p = 0.68	
[35]	Chinese Han individuals	1322 adults	18 SNPs associated with serum uric acid	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 mmol/L change in urate levels	TH-BMD, 0.19 (−0.36, 0.74)	p = 0.50	
						FN-BMD, −0.19 (−0.42, 0.81)	p = 0.53	
						LS-BMD, 0.39 (−0.26, 0.98)	p = 0.26	
						TF-BMD, −0.29 (−0.60, 0.01)	p = 0.06	

Table 1 (continued)

Exposure	Cohort(s)	Number	Genetic variant(s)	MR method	Unit	Casual effect estimate	<i>p</i>	Ref
Phosphate	School-based cross-sectional study from Helsinki	183 children and adolescents	3 SNPs within the FGF23 gene	Instrumental variable regression model, 2SLS	1 g/cm ² change in BMD per 1 ng/L change in S-FGF23	PINP, 0.11 (−1.54, 1.75) b-CTX, −1.45 (−3.44, 0.27) TH-BMD, 0.6 (−0.27, 1.53)	<i>p</i> = 0.10 <i>p</i> = 0.07 <i>p</i> = 0.17	[33]
Calcium milk intake	Summary data from two	BMD, 32,961	1 SNP associated with lactose intolerance	Published GWAS summary data, IVW approach	N/A	N/A	NS	[41]
Late puberty	Summary data from two consortia (ReproGen consortium and GEFOS consortium)	Puberty, 39,486 women, 55,871 men BMD, 32,961	331 SNPs associated with the onset of menarche 43 SNPs associated with age at voice break	Published GWAS summary data, IVW approach, MR-base	SD change in BMD per 1 year earlier onset of puberty	Age at menarche: FA-BMD, 0.09 FN-BMD, 0.12 LS-BMD, 0.17 Age at voice break: FA-BMD, 0.05 FN-BMD, 0.002 LS-BMD, 0.12	<i>p</i> = 0.18 <i>p</i> = 0.06 <i>p</i> = 0.005 <i>p</i> = 0.70 <i>p</i> = 0.99 <i>p</i> = 0.0003	[32]

BMD, bone mineral density; *BMC*, bone mineral content; *BMI*, body mass index; *FN*, femoral neck; *TH*, total hip; *LS*, lumbar spine; *FA*, forearm; *UL*, upper limbs; *LL*, lower limbs; *SK*, skull; *PE*, pelvis; *eBMD*, estimated BMD from ultrasound; *hsCRP*, highly sensitive C-reactive protein; *GWAS*, genome wide association study; *IVW*, inverse variant weighted; *WM*, weighted median; *SD*, standard deviation; *N/A*, not applicable; *NS*, not significant; *2SLS*, two-stage least square

by performing an additional analysis using summary data from the well-powered SUNLIGHT and GEFOS consortia where the null results remained consistent. Furthermore, Li et al. [39] using the four aforementioned vitamin D-associated SNPs found no evidence for a causal effect of vitamin D levels on BMD and bone turnover markers in a population of Chinese postmenopausal women ($N = 1824$). Finally, Larsson et al. [40•] using data from the GEFOS consortium and UK BioBank study have also recently found that vitamin D levels had no effect on DXA-measured BMD ($N = 32,965$). However, they observed that elevated vitamin D levels could exert a small decrease in estimated BMD derived from heel ultrasound ($N = 142,487$). Although the genetic variants have modest effects on vitamin D levels and explain small proportion of the trait variance, the aforementioned studies using summary level data were well powered to investigate causal associations. Very recently, we have also shown lack of a causal relationship between vitamin D levels and fractured risk, investigated in 37,857 cases and 227 116 controls [45].

These results should be interpreted with caution since the MR efforts have examined a linear relationship between vitamin D levels and BMD. Possible threshold-dependent effects (effects present only in a subgroup with low vitamin D levels) are not examined by this approach. Extreme deficits in vitamin D are known to influence bone metabolism and result in disease (i.e., rickets, osteomalacia). In contrast, the MR setting is drawn in the general population, typically including relatively healthy elderly adults, so the findings might not be applicable to very old and frail people where vitamin D deficiency is frequently present. Another aspect relates to gene x environment (GxE) interactions, which can be challenging to consider in casual inference analyses. It has been postulated that vitamin D levels may be subject to GxE interactions [46, 47]. However, these interactions remain difficult to detect (as testing requires very large sample sizes which are not yet available). Until then, detecting the main effect of a genotype will be more reliable than testing for GxE interactions [48]. Either way, once GxE interactions are detected demonstrating that the exposure differs quantitatively between individuals, then the MR should be restricted to the specific subgroups where the environmental exposure is homogeneous.

Limitations

In order to obtain unbiased estimates of causality, all three crucial assumptions of MR must be fulfilled. However, the verification of the assumptions is difficult, particularly assessing canalization and pleiotropic effects. In general, the results of MR are said to be robust when multiple methods to assess the MR assumptions are applied and the observed effects still stand. Most importantly, the interpretation of MR studies should be

made with caution and with substantial knowledge of the underlying biology. There are multiple factors that can bias the estimates of MR studies: (1) *Insufficient power*—i.e., the probability that the null hypothesis can be rejected in the presence of true association between the biomarker and disease. If the genetic instrument explains a small proportion of the trait variance, a sufficiently powered sample size will be required to detect effect and sample size calculations should be performed and considered for the interpretation of the findings. (2) *Weak instrument bias*—strong instruments will force the association to be independent of confounders. With weak instruments, confounders are not equally balanced between genotype groups and the confounders can explain a given difference in phenotype more strongly than the instruments. Therefore, the instrument should be robustly associated with the exposure of interest. Similarly, an instrument may lack sufficient power when the outcome is only affected by large changes in the exposure. This is particularly relevant for complex traits where common genetic variants typically have a small effect. Therefore, the combined use of multiple variants as instruments will be warranted to achieve sufficient power. (3) *Pleiotropy*—i.e., when a gene or variant is associated with multiple traits. Even in the presence of a causal effect, the effect can still be due to other factors controlled by the genetic effect. Pleiotropy can be vertical (when genetic variants influence other factors downstream of the primary trait) and horizontal (when the genetic variants influence multiple traits separately). This is nicely illustrated in recent work examining the influence of adiposity and BMD [27••], where an effect on BMD can be mediated by fat mass, lean mass, or both, drawing the need for careful interpretation of the findings. (4) *Population stratification*—i.e., differences in genetic structure between subpopulations masked in the population under investigation. The genetic association between the instrument and the outcome should not be driven (or attenuated) by population stratification. Other potential ethnic differences between the discovery (exposure) and the target (outcome) settings (i.e., allele frequencies, linkage disequilibrium structure) should be considered in the interpretation of the MR findings as they reduce the strength of genetic instruments. (5) *Canalization/developmental compensation* due to operation of compensatory processes during development that may resist the phenotypic changes that result from the genetic variants being used as an instrument.

Clinical Implication

The major advantage of the MR approach is that it can help overcome the expensive costs of running an RCT, by helping in the prioritization of interventions directed towards causal pathways. The selection of interventions based on genetic evidence could have a substantial impact on clinical practice with major considerable utility in primary prevention. In

cardiovascular epidemiology, for example, PCSK9 (protein which influences LDL-C levels) has been identified as a potential drug target using MR methods [49]. Recently, phase II clinical trials have proven the safety and efficacy of the monoclonal PCSK9 antibodies [50]. Furthermore, the strengthening of the causal relationship between modifiable exposures and a wide range of outcomes related to complex diseases can help us improve the drug target identification and validation processes, i.e., the MR approach will contribute to robust determination of the role of factors within biological pathways. For example, a recent study has illustrated how drug mechanisms with genetic support are shown to succeed twice as often as those without it (from phase I to approval) [51]. In fact, this is the case for osteoporosis drugs as the highest degree of genetic support for drug target indications was related to the musculoskeletal (BMD), metabolic, and blood categories [52]. In addition, MR can help in identifying adverse effects and drug repurposing [53]. For example, it has been widely recognized that statins, commonly used for prevention of CHD, increase the risk of type 2 diabetes [54]. After the clinical trials, using MR approach, it has been shown that the risk of type 2 diabetes can be partially explained by inhibition of the HMGCR gene (produces enzyme targeted by statins) [55]. In principle, this example illustrates (in retrospective) the potential of the MR approach to inform RCT before their execution.

Looking back to bone-related phenotypes, most MR methods have evaluated the causality of specific exposures. To date, there are no studies that have investigated the causality of specific drug targets for osteoporosis. One novel osteoporotic treatment is the use of Romosozumab, a monoclonal antibody that targets sclerostin. However, recent trials have shown that Romosozumab is associated with (small yet real) increased risk of cardiovascular adverse events. This way, MR studies are warranted to evaluate the causal relation of Romosozumab treatment with this adverse effect, by investigating whether variations in the *SOST* gene are associated with cardiovascular or other adverse events.

Conclusions

The Mendelian randomization (MR) approach is a robust strategy to determine causal relationships between risk factors and diverse health-related outcomes, including bone health. While still in its infancy, the MR approach has been used to evaluate multiple factors mostly related to bone mineral density variation and a few for fracture risk. Given the advent of large-scale GWAS identifying hundreds to thousands of genetic variants robustly associated with bone traits, together with the clear benefits of the MR approach to prioritize interventions of RCT, repurpose existing medications, and prediction of adverse effects, it is expected that many of the unsolved epidemiological

questions of observational studies will be solved and better treatments for patients will emerge in the clinic.

Acknowledgments Katerina Trajanoska and Fernando Rivadeneira are supported by the Netherlands Scientific Organization (NWO) and ZonMW Project number: NW O/ZONMW-VIDI-0 16-136-367.

Compliance with Ethical Standards

Conflict of Interest Katerina Trajanoska and Fernando Rivadeneira declare no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. *J Clin Endocrinol Metab* [Internet]. 1995;80(4):1052–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7714065>
2. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. *Am J Clin Nutr* [Internet]. 1995;61(5):1140–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7733040>
3. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmannian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. *Ann Intern Med* [Internet]. 1994;120(2):97–103. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8256988>
4. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* [Internet]. 1997;337(10):670–6. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJM199709043371003>
5. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *Can Med Assoc J* [Internet]. 2010;182(17):1864–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20940232>
6. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016. *Endocr Pract* [Internet]. 2016;22(Supplement 4):1–42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27662240>
7. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. *Ann Intern Med* [Internet]. 1996;124(4):400–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8554248>
8. Khaw K-T, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA, et al. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. *Lancet Diabetes Endocrinol* [Internet]. 2017;5(6):438–47. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28461159>
9. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* [Internet]. 2005;365(9471):1621–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15885294>
10. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med* [Internet]. 2006;354(7):669–83. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa055218>
11. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women. *JAMA* [Internet]. 2010;303(18):1815. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20460620>
12. Jones DS, Podolsky SH. The history and fate of the gold standard. *Lancet* [Internet]. 2015;385(9977):1502–3. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25933270>
13. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. *Annu Rev Genomics Hum Genet* [Internet]. 2015;16(1):327–50. Available from: <http://www.annualreviews.org/doi/10.1146/annurev-genom-090314-050016>
14. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. *Am J Epidemiol* [Internet]. 2006;163(5):397–403. Available from: <http://academic.oup.com/aje/article/163/5/397/61279/Limits-to-Causal-Inference-based-on-Mendelian>
15. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. *Am J Hum Genet* [Internet]. 2017;101(1):5–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28686856>
16. Davies NM, Smith GD, Windmeijer F, Martin RM. Issues in the reporting and conduct of instrumental variable studies. *Epidemiology* [Internet]. 2013;24(3):363–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23532055>
17. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(June):512–25.
18. Jones KL, Smith DW, Ulleland CN, Streissguth P. Pattern of malformation in offspring of chronic alcoholic mothers. *Lancet* (London, England) [Internet]. 1973;1(7815):1267–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/4126070>
19. Kelly Y, Iacovou M, Quigley M, Gray R, Wolke D, Kelly J, et al. Light drinking versus abstinence in pregnancy - behavioural and cognitive outcomes in 7-year-old children: a longitudinal cohort study. *BJOG An Int J Obstet Gynaecol* [Internet]. 2013;120(11):1340–7. <https://doi.org/10.1111/1471-0528.12246>.
20. Zuccolo L, Lewis SJ, Davey Smith G, Sayal K, Draper ES, Fraser R, et al. Prenatal alcohol exposure and offspring cognition and school performance. A ‘Mendelian randomization’ natural experiment. *Int J*

- Epidemiol [Internet]. 2013;42(5):1358–70. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyt172>
21. Birley AJ, James MR, Dickson PA, Montgomery GW, Heath AC, Martin NG, et al. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. *Hum Mol Genet* [Internet]. 2009;18(8):1533–42. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/19193628>
 22. Lewis SJ, Zuccolo L, Davey Smith G, Macleod J, Rodriguez S, Draper ES, et al. Fetal alcohol exposure and IQ at age 8: evidence from a population-based birth-cohort study. *PLoS One* [Internet]. 2012;7(11):e49407. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23166662>
 23. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) CRPCHDGC, Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. *BMJ* [Internet]. 2011;342:d548. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21325005>
 24. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically Elevated Lipoprotein (a) and increased risk of myocardial infarction. *JAMA* [Internet]. 2009;301(22):2331. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19509380>
 25. Manousaki D, Mokry LE, Ross S, Goltzman D, Richards JB. Mendelian randomization studies do not support a role for vitamin D in coronary artery disease. *Circ Cardiovasc Genet* [Internet]. 2016;9(4):349–56. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27418593>
 26. Kumar J, Ingelsson E, Lind L, Fall T. No evidence of a causal relationship between plasma homocysteine and type 2 diabetes: a mendelian randomization study. *Front Cardiovasc Med* [Internet]. 2015;2:11. Available from: http://www.frontiersin.org/Cardiovascular_Epidemiology/10.3389/fcvm.2015.00011/abstract
 27. •• Kemp JP, Sayers A, Smith GD, Tobias JH, Evans DM. Using Mendelian randomization to investigate a possible causal relationship between adiposity and increased bone mineral density at different skeletal sites in children. *Int J Epidemiol* [Internet]. 2016;45(5):1560–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27215616>. **This is an example of well conducted MR study using multiple MR extensions in order to provide robust causal estimates. Overall, the findings suggest that adiposity is casually related to increase bone mineral density in children**
 28. Timpson NJ, Sayers A, Davey-Smith G, Tobias JH. How does body fat influence bone mass in childhood? A Mendelian randomization approach. *J Bone Miner Res* [Internet]. 2009;24(3):522–33. Available from: <http://doi.wiley.com/10.1359/jbmr.081109>
 29. Warodomwicht D, Sritara C, Thakkinian A, Chailurkit L-O, Yamwong S, Ratanachaiwong W, et al. Causal inference of the effect of adiposity on bone mineral density in adults. *Clin Endocrinol (Oxf)* [Internet]. 2013;78(5):694–9. Available from: <http://doi.wiley.com/10.1111/cen.12061>
 30. Cousminer DL, Mitchell JA, Chesi A, Roy SM, Kalkwarf HJ, Lappe JM, et al. Genetically determined later puberty impacts lowered bone mineral density in childhood and adulthood. *J Bone Miner Res* [Internet]. 2017; Available from: <http://doi.wiley.com/10.1002/jbmr.3320>
 31. • Ahmad OS, Leong A, Miller JA, Morris JA, Forgetta V, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes and glycemic traits on bone mineral density. *J Bone Miner Res* [Internet]. 2017;32(5):1072–81. Available from: <http://doi.wiley.com/10.1002/jbmr.3063>. **Well-powered study showing weak positive effects of T2D and or genetically increased fasting glucose on bone mineral density.**
 32. Oei L, Campos-Obando N, Dehghan A, Oei EHG, Stolk L, van Meurs JBJ, et al. Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study. *Osteoporos Int* [Internet]. 2014;25(4):1247–54. Available from: <http://link.springer.com/10.1007/s00198-013-2578-0>
 33. Huang JV, Schooling CM. Inflammation and bone mineral density: a Mendelian randomization study. *Sci Rep* [Internet]. 2017;7(1):8666. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28819125>
 34. Pekkinen M, Laine CM, Mäkitie R, Leinonen E, Lamberg-Allardt C, Viljakainen H, et al. FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents. *Bone* [Internet]. 2015;71:124–30. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S875632821400386X>
 35. Dalbeth N, Topless R, Flynn T, Cadzow M, Bolland MJ, Merriman TR. Mendelian randomization analysis to examine for a causal effect of urate on bone mineral density. *J Bone Miner Res* [Internet]. 2015;30(6):985–91. <https://doi.org/10.1002/jbmr.2434>.
 36. Xiong A, Yao Q, He J, Fu W, Yu J, Zhang Z. No causal effect of serum urate on bone-related outcomes among a population of postmenopausal women and elderly men of Chinese Han ethnicity—a Mendelian randomization study. *Osteoporos Int* [Internet]. 2016;27(3):1031–9. Available from: <http://link.springer.com/10.1007/s00198-015-3341-5>
 37. Gan W, Clarke RJ, Mahajan A, Kulohoma B, Kitajima H, Robertson NR, et al. Bone mineral density and risk of type 2 diabetes and coronary heart disease: a Mendelian randomization study. *Wellcome Open Res* [Internet]. 2017;2:68. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28989980>
 38. Leung A, Rehman W, Dastani Z, Greenwood C, Timpson N, Langsetmo L, et al. The causal effect of vitamin D binding protein (DBP) levels on calcemic and cardiometabolic diseases: a Mendelian randomization study. *Minelli C, editor. PLoS Med* [Internet]. 2014;11(10):e1001751. <https://doi.org/10.1371/journal.pmed.1001751>.
 39. Li S-S, Gao L-H, Zhang X-Y, He J-W, Fu W-Z, Liu Y-J, et al. Genetically low vitamin D levels, bone mineral density, and bone metabolism markers: a Mendelian randomisation study. *Sci Rep* [Internet]. 2016;6(1):33202. Available from: <http://www.nature.com/articles/srep33202>
 40. • Larsson SC, Melhus H, Michaëlsson K. Circulating serum 25-hydroxyvitamin D levels and bone mineral density: Mendelian randomization study. *J Bone Miner Res* [Internet]. 2018; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29338102>. **Well-powered study that does not support the causal association between genetically elevated 25OHD concentrations and higher BMD in generally healthy populations.**
 41. Yang Q, Lin SL, Au Yeung SL, Kwok MK, Xu L, Leung GM, et al. Genetically predicted milk consumption and bone health, ischemic heart disease and type 2 diabetes: a Mendelian randomization study. *Eur J Clin Nutr* [Internet]. 2017; Available from: <http://www.nature.com/doi/10.1038/ejcn.2017.8>
 42. Holick MF. Vitamin D deficiency. *N Engl J Med* [Internet]. 2007;357(3):266–81. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMra070553>
 43. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* [Internet]. 2010;376(9736):180–8. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0140673610605880>
 44. Haddad JG. Transport of vitamin D metabolites. *Clin Orthop Relat Res* [Internet]. 1979;142:249–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/91467>
 45. Trajanoska K, Morris J, et al., Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study. *BMJ* 2018 [in press]

46. Graafmans WC, Lips P, Ooms ME, Van Leeuwen JPTM, Pols HAP, Uitterlinden AG. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin d receptor genotype. *J Bone Miner Res* [Internet]. 1997;12(8):1241–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9258754>
47. Elnenaï MO, Chandra R, Mangion T, Moniz C. Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation. *Br J Nutr* [Internet]. 2011;105(01):71–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20727239>
48. Smith GD, Shah E. Mendelian randomization: genetic variants as instruments for strengthening causal inference in observational studies. In: National Research Council (US) Committee on Advances in Collecting and Utilizing Biological Indicators and Genetic Information in Social Science Surveys, Weinstein M, Vaupel JW, Wachter KW, editors. *Biosocial Surveys*. Washington: Natl Acad. 2008. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK62433/>.
49. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in *PCSK9*, low LDL, and protection against coronary heart disease. *N Engl J Med* [Internet]. 2006;354(12):1264–72. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa054013>
50. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia. *J Am Coll Cardiol* [Internet]. 2014;63(23):2531–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24691094>
51. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. *Nat Genet* [Internet]. 2015;47(8):856–60. Available from: <http://www.nature.com/articles/ng.3314>
52. Hurle MR, Nelson MR, Agarwal P, Cardon LR. Impact of genetically supported target selection on R&D productivity. *Nat Rev Drug Discov* [Internet]. 2016; Available from: <http://www.nature.com/doiifinder/10.1038/nrd.2016.187>
53. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. *Int J Epidemiol* [Internet]. 2017;46(6):2078–89. Available from: <http://academic.oup.com/ije/article/46/6/2078/4430993>
54. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* (London, England) [Internet]. 2010;375(9716):735–42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20167359>
55. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* [Internet]. 2015;385(9965):351–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25262344>